InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Share Price

Current share price for PAR : $0.155 0.005 (3.13%)+

Paradigm Biopharmaceuticals Ltd. (PAR), an ASX-listed company, is engaged in researching and developing therapeutic products for human use.

PAR General Information +

ASX Code PAR
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 90
PAR Share Price $0.155
Day High $0.165
Day Low $0.155
Last Close $0.160
PAR Share Price Movement $0.01 ( 3.13% )
Prices as at 16:40, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Paradigm Biopharmaceuticals Limited (PAR) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Paradigm Biopharmaceuticals Limited (PAR) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Paradigm Biopharmaceuticals Limited (PAR) price-sensitive announcements

PAR - PAR Completes Enrolment in Pivotal Phase 3
Paradigm Biopharmaceuticals Ltd. has successfully completed enrolment for its pivotal Phas
Paradigm Biopharmaceuticals Limited (PAR)
15 Jun 2026 | 9:11 AM
PAR - Results of Share Purchase Plan
Paradigm Biopharmaceuticals Ltd. announced the successful completion of their Share Purcha
Paradigm Biopharmaceuticals Limited (PAR)
1 Jun 2026 | 10:34 AM
PAR - DSMB 20% Review Supports Phase 3, Moldova Activated
Paradigm Biopharmaceuticals Ltd announced that its Phase 3 PARA_OA_012 clinical trial will
Paradigm Biopharmaceuticals Limited (PAR)
30 Apr 2026 | 8:13 AM
PAR - March 2026 Quarterly Activities Report & Appendix 4C
Paradigm Biopharmaceuticals Limited's March 2026 Quarterly Activities Report highlights si
Paradigm Biopharmaceuticals Limited (PAR)
27 Apr 2026 | 10:07 AM

Paradigm Biopharmaceuticals Limited (PAR) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Paradigm Biopharmaceuticals Limited (PAR)
ORDINARY FULLY PAID
Health Care $91 Change of Director's Interest Notice 18 Jun 2026 5:46PM $0.180 $0.155 fallen by 13.89%
Paradigm Biopharmaceuticals Limited (PAR)
ORDINARY FULLY PAID
Health Care $91 Change of Director's Interest Notice 18 Jun 2026 5:46PM $0.180 $0.155 fallen by 13.89%
Paradigm Biopharmaceuticals Limited (PAR)
ORDINARY FULLY PAID
Health Care $91 Application for quotation of securities - PAR 18 Jun 2026 5:29PM $0.180 $0.155 fallen by 13.89%
Paradigm Biopharmaceuticals Limited (PAR)
ORDINARY FULLY PAID
Health Care $91 Listing of Options - Top 20 Holders and Distribution Reports 17 Jun 2026 10:52AM $0.160 $0.155 fallen by 3.13%
Paradigm Biopharmaceuticals Limited (PAR)
ORDINARY FULLY PAID
Health Care $91 Application for quotation of securities - PAR 17 Jun 2026 10:50AM $0.160 $0.155 fallen by 3.13%
Paradigm Biopharmaceuticals Limited (PAR)
ORDINARY FULLY PAID
Health Care $91 PAR Completes Enrolment in Pivotal Phase 3 15 Jun 2026 9:11AM $0.150 $0.155 risen by 3.33%

PAR Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$16.24 -$5.20 -74.20% 0.00 0.00 0.00% 0.0%
2024A -$58.65 -$20.00 11.40% 0.00 0.00 0.00% 0.0%
2023A -$52.00 -$18.00 10.20% 0.00 0.00 0.00% 0.0%

PAR Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
CSL Limited (CSL) $56,344M 0.1108 -0.1296 0.0166 12.6157 14.4937 14.2573 3.79% 3.06% 3.19%
Clinuvel Pharmaceuticals Limited (CUV) $507M 0.0287 -0.0028 0.1257 13.9972 14.0363 12.4690 0.50% 0.70% 1.53%
Mesoblast Limited (MSB) $2,693M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Paradigm Biopharmaceuticals Limited (PAR) $94M -0.7420 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,321M -1.3893 0.0000 -0.1304 0.0000 291.9926 335.7602 0.00% 0.00% 0.00%

PAR Directors

Name Position Start Date
Mr Paul Rennie Executive Director, Managing Director, Executive Chairman 2 May 2014
Mr Amos Meltzer Non-Executive Director 9 Dec 2020
Mr Matthew James Fry Non-Executive Director 4 Mar 2024

Paradigm Biopharmaceuticals Limited (PAR) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
2 Jun 2026 RENNIE, Paul Buy Direct Shares 176,470 $0.170 $30,000.000
2 Jun 2026 RENNIE, Paul Buy Indirect Shares 352,940 $0.170 $60,000.000
2 Jun 2026 FRY, Matthew Buy Indirect Shares 176,470 $0.170 $30,000.000

See all changes in directors' interest & trades for Paradigm Biopharmaceuticals Limited (PAR) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

PAR Management

Name Position
Abby Macnish Interim Company Secretary

PAR Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Paradigm Biopharmaceuticals Limited (PAR). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
20,726,750 (5.32%) Paul Rennie and related companies
20,216,245 (5.19%) Citicorp Nominees Pty Limited
14,090,211 (3.61%) HSBC Custody Nominees (Australia) Limited

PAR Calendar of Events

Date Event
26 February 2027 Report (Interim)
28 August 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.